AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29739384 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (CBT) intervention plus Treatment as Usual (TAU)
Number of subjects: 120
Study 29739384 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study 27498652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr Michaels® (Soratinex®) herbal skin-care products
Number of subjects: 142
Study 27498652 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral ointments and medicinal bathing oil)
Number of subjects: 142
Study 24916165 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg Fe as FeSO₄, 4 days/week for 38 weeks)
Number of subjects: 73
Study 24916165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24916165 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 73
Study 22257480 — intervention group
Group type: EXPERIMENTAL
Intervention: ilaprazole 5mg
Number of subjects: 12
Study 22257480 — intervention group
Group type: EXPERIMENTAL
Intervention: ilaprazole 10mg
Number of subjects: 12
Study 22257480 — intervention group
Group type: EXPERIMENTAL
Intervention: ilaprazole 20mg
Number of subjects: 12
Study 22257480 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20mg
Number of subjects: 12
Study 19152958 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 482
Study 19152958 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 482
Study 19152958 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Duloxetine 60 mg/d
Number of subjects: 482
Study 19152958 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Duloxetine 120 mg/d
Number of subjects: 482
Study 19152958 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 482
Study 17482343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 148
Study 17482343 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 148
Study 16278493 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Number of subjects: 1
Study 16278493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 11879862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril for 2 years
Number of subjects: 26
Study 11879862 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 26
Study 10439732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 1 mg/kg
Number of subjects: 47
Study 10439732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 2 mg/kg
Number of subjects: 47
Study 10439732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 3 mg/kg
Number of subjects: 47
Study 10439732 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 7486464 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 144
Study 7486464 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal-conjugate vaccine
Number of subjects: 144
Study 7486464 — intervention group
Group type: EXPERIMENTAL
Intervention: HIB-conjugate vaccine
Number of subjects: 144
Study 2240380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides
Number of subjects: 292
Study 2240380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving aminoglycosides)
Number of subjects: 292
Study 323297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (40, 80, or 160 mg)
Number of subjects: 36
Study 323297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (80 mg, multiple doses)
Number of subjects: 36
Study 323297 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 36
Study 323297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 36
Study 323297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (same doses as methylprednisolone sodium phosphate)
Number of subjects: 36
Study 30886732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg two times a day
Number of subjects: 0
Study 30886732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times a day
Number of subjects: 0
Study 30886732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29205786 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg subcutaneous dose
Number of subjects: 44
Study 27521353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) for 2 weeks
Number of subjects: 814
Study 27521353 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 814
Study 25031362 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal safety awareness program
Number of subjects: 213
Study 25031362 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study 22178855 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable trace mineral supplement (ITM; n = 42; 7 mL subcutaneous; MultiMin, Fort Collins, CO)
Number of subjects: 99
Study 22178855 — intervention group
Group type: COMPARATOR
Intervention: saline‐injected control (Control; n = 42)
Number of subjects: 99
Study 19957034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion short‐wire system
Number of subjects: 71
Study 17385061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g resistant maltodextrin
Number of subjects: 13
Study 17385061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g resistant maltodextrin
Number of subjects: 13
Study 17385061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beverage not containing resistant maltodextrin)
Number of subjects: 13
Study 16343383 — intervention group
Group type: EXPERIMENTAL
Intervention: Viatim (combined hepatitis A and typhoid fever vaccine)
Number of subjects: 360
Study 16343383 — intervention group
Group type: COMPARATOR
Intervention: Monovalent HA vaccine
Number of subjects: 360
Study 16343383 — intervention group
Group type: COMPARATOR
Intervention: Monovalent Vi vaccine
Number of subjects: 360
Study 12631173 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic gel (Oraqix) containing 25 mg/g prilocaine and 25 mg/g lidocaine, applied for 30 seconds prior to periodontal debridement.
Number of subjects: 130
Study 12631173 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, applied for 30 seconds prior to periodontal debridement.
Number of subjects: 130
Study 12631173 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic gel (Oraqix)
Number of subjects: 130
Study 12631173 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 130
Study 10642370 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution (C)
Number of subjects: 8
Study 10642370 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate + 4.2% MCT solution (C+M)
Number of subjects: 8
Study 10642370 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo (P)
Number of subjects: 8
Study 8891962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute trauma patients
Number of subjects: 11
Study 8891962 — intervention group
Group type: COMPARATOR
Intervention: Control group (same‐day elective surgery patients)
Number of subjects: 11
Study 2068469 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Number of subjects: 80
Study 2068469 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (80 mg intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Number of subjects: 80
Study 6859471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0
Study 6859471 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 30888478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg daily for 6 months
Number of subjects: 289
Study 30888478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 29513659 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-targeted screening arm
Number of subjects: 160
Study 29513659 — intervention group
Group type: COMPARATOR
Intervention: Targeted testing arm
Number of subjects: 160
Study 29513659 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted arm after cross-screening
Number of subjects: 160
Study 29513659 — intervention group
Group type: COMPARATOR
Intervention: Acceptance rate in targeted arm
Number of subjects: 160
Study 29513659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance rate in non-targeted arm
Number of subjects: 160
Study 27591157 — intervention group
Group type: EXPERIMENTAL
Intervention: PID‐C (Personalized Intervention for Depressed Patients with COPD)
Number of subjects: 101
Study 27591157 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA (Problem Solving‐Adherence)
Number of subjects: 101
Study 27591157 — intervention group
Group type: COMPARATOR
Intervention: Control (Usual Care)
Number of subjects: 101
Study 25198265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 36
Study 25198265 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine (25 mg) plus Doxylamine (12.5 mg)
Number of subjects: 36
Study 22475593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (180 mg pyronaridine and 60 mg artesunate, administered once daily for 3 days)
Number of subjects: 1271
Study 22475593 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine plus artesunate (250 mg mefloquine and 100 mg artesunate, administered once daily for 3 days)
Number of subjects: 1271
Study 22475593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 1271
Study 22475593 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine plus artesunate
Number of subjects: 1271
Study 22475593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1271
Study 20813564 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% podophyllin resin with 5% acyclovir cream (PA)
Number of subjects: 42
Study 20813564 — intervention group
Group type: COMPARATOR
Intervention: 25% podophyllin resin (P)
Number of subjects: 42
Study 20813564 — intervention group
Group type: COMPARATOR
Intervention: 25% podophyllin resin with 1% penciclovir cream (PP)
Number of subjects: 42
Study 18089329 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 127
Study 18089329 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 127
Study 16258087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for 5 years)
Number of subjects: 829
Study 16258087 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional treatment)
Number of subjects: 829
Study 11849730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (5000 lux for 5 h from 00:00 to 05:00 h)
Number of subjects: 9
Study 11849730 — intervention group
Group type: COMPARATOR
Intervention: Dim light (10 lux for 5 h from 00:00 to 05:00 h)
Number of subjects: 9
Study 11849730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 9
Study 9489596 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 10 mg
Number of subjects: 5
Study 9489596 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 25 mg
Number of subjects: 5
Study 9489596 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 5
Study 8172095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)2D) treatment (1 micrograms/d for 4 d)
Number of subjects: 35
Study 8172095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)2D) treatment
Number of subjects: 35
Study 8172095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3351700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous metoclopramide
Number of subjects: 22
Study 31436322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (nCT) with cisplatin 100 mg/m2 on day 1 and 750 mg/m2 5-fluorouracil over 24 hours on days 1-5 for three 21-day cycles
Number of subjects: 165
Study 31436322 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with the same chemotherapy regimen plus 40 Gy radiotherapy
Number of subjects: 165
Study 31436322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (nCT)
Number of subjects: 165
Study 31436322 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 165
Study 31436322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nCT and nCRT
Number of subjects: 165
Study 30563808 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention with Fitbit integration
Number of subjects: 243
Study 30563808 — intervention group
Group type: COMPARATOR
Intervention: Web-based computer-tailored intervention without Fitbit integration (Control)
Number of subjects: 243
Study 26382634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 41
Study 26382634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24473436 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-6 (rhIL-6)
Number of subjects: 9
Study 24473436 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 23171567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), n = 60, energy dose of 6 J per tender point, treated three times per week for four weeks (total of 12 sessions).
Number of subjects: 120
Study 23171567 — intervention group
Group type: COMPARATOR
Intervention: Control group (CLLLT), n = 60, treated three times per week for four weeks (total of 12 sessions).
Number of subjects: 120
Study 23171567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), n = 60.
Number of subjects: 120
Study 23171567 — intervention group
Group type: COMPARATOR
Intervention: Control group (CLLLT), n = 60.
Number of subjects: 120
Study 20631462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (two injections, 2 weeks apart, n = 150)
Number of subjects: 313
Study 20631462 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MPA) (1 injection of 40 mg and 1 sham injection 2 weeks later, n = 155)
Number of subjects: 313
Study 20631462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20
Number of subjects: 313
Study 20631462 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MPA)
Number of subjects: 313
Study 20631462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 and MPA
Number of subjects: 313
Study 17397005 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP) for CIN3 treatment
Number of subjects: 201
Study 17397005 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 non-European variants
Number of subjects: 201
Study 15105817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 20‐25 mg of triamcinolone acetonide
Number of subjects: 28
Study 15105817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravitreal injection)
Number of subjects: 28
Study 12498843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 140
Study 12498843 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 140
Study 12498843 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(methyl methacrylate) IOL (PMMA)
Number of subjects: 140
Study 12498843 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified PMMA (HSM PMMA) IOL
Number of subjects: 140
Study 9834303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1653
Study 9834303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and warfarin
Number of subjects: 1653
Study 9834303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 1653
Study 8014643 — intervention group
Group type: COMPARATOR
Intervention: Anatomic Modular Knee (AMK)
Number of subjects: 100
Study 8014643 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller Galante I (MG I)
Number of subjects: 100
Study 2674744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia-induced somatotropin (STH) secretion
Number of subjects: 24
Study 2674744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of luliberin
Number of subjects: 24
Study 5675432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.5 g)
Number of subjects: 6
Study 5675432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (0.50 mmole/liter)
Number of subjects: 6
Study 5675432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.8 g)
Number of subjects: 6
Study 5675432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6
Study 5675432 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate
Number of subjects: 6
Study 6777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine 50 mg
Number of subjects: 10
Study 6777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine 75 mg
Number of subjects: 10
Study 6777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine 125 mg
Number of subjects: 10
Study 6777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 75 mg
Number of subjects: 10
Study 6777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 10
Study 6777458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31813228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay counselor-delivered problem-solving therapy
Number of subjects: 19
Study 29932584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound rectus sheath block of ropivacaine with systemic analgesia
Number of subjects: 58
Study 29932584 — intervention group
Group type: COMPARATOR
Intervention: Only systemic analgesia
Number of subjects: 58
Study 25680658 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1006
Study 25680658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study 23588864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200 mg added to treatment)
Number of subjects: 0
Study 23588864 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl (TDF) (initial dose of 25 µg/h, increased by 25 µg/h as needed)
Number of subjects: 0
Study 23588864 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Group K)
Number of subjects: 0
Study 20924769 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone PEEK cages
Number of subjects: 72
Study 20924769 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autografts
Number of subjects: 72
Study 19065670 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 69
Study 19065670 — intervention group
Group type: COMPARATOR
Intervention: Adefovir 10 mg/day
Number of subjects: 69
Study 17596805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent (CAIV-T)
Number of subjects: 3174
Study 15099138 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in font and case during study and test
Number of subjects: 0
Study 15099138 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of a secondary task during study
Number of subjects: 0
Study 11231746 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet behavior therapy
Number of subjects: 91
Study 11231746 — intervention group
Group type: COMPARATOR
Intervention: Internet education
Number of subjects: 91
Study 9854458 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (subcutaneous)
Number of subjects: 13
Study 9854458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7840403 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 57
Study 7840403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 57
Study 7840403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 57
Study 7840403 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 57
Study 7840403 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 57
Study 7840403 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 57
Study 7840403 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 57
Study 7840403 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine
Number of subjects: 57
Study 2966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 200
Study 2966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 200
Study 2966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous streptokinase and PTCA
Number of subjects: 200
Study 2966565 — intervention group
Group type: COMPARATOR
Intervention: rt-PA alone
Number of subjects: 200
Study 2966565 — intervention group
Group type: COMPARATOR
Intervention: rt-PA followed by immediate angioplasty
Number of subjects: 200
Study 2966565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase with angioplasty
Number of subjects: 200
Study 2966565 — intervention group
Group type: COMPARATOR
Intervention: rt-PA with angioplasty
Number of subjects: 200
Study 30550415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise program
Number of subjects: 264
Study 31243560 — intervention group
Group type: EXPERIMENTAL
Intervention: CISB + GA
Number of subjects: 85
Study 31243560 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 85
Study 28682922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session (treadmill; 40 min; 55% VO2peak)
Number of subjects: 109
Study 28682922 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 109